Vedolizumab-5056: Clinical Effectiveness of Vedolizumab Used in Frames of Drug Program for Crohn’s Disease Treatment in Poland – Prospective, Observational Study Considering Fatigue and Other Patient-reported-outcomes (PROs) (POLONEZ II)

First published 28/01/2020

Last updated 25/06/2024

EU PAS number:

EUPAS32716

Study

Finalised

Documents

Study protocol

Initial protocol

Vedolizumab-5056-clinical-study-protocol-redact.pdf

English (11.61 MB - PDF)View document

Study results

Study report

Vedolizumab-5056-clinical-study-report-redact.pdf

English (1.29 MB - PDF)View document

Other information

ENCePP Seal

ENCePP Seal documents

Secondary tabs